Somatostatin pp 333-336 | Cite as

Somatostatin Octapeptide in the Medical Treatment of Acromegaly

  • G. M. Besser
  • J. A. H. Wass
Part of the Serono Symposia, USA book series (SERONOSYMP)


Somatostatin lowers growth hormone (GH) in patients with acromegaly but it has a short half life in the circulation and thus cannot be used for medical treatment. Recently an octapeptide analogue (SMS 201–995) of somatostatin has been developed with a much longer half-life and which has clear therapeutic potential in patients with growth hormone secreting tumors.

Somatostatin octapeptide causes the suppression of growth hormone for 3, 5 and 9 hours after 50, 100 and 200 μg respectively. 400 μg subcutaneously caused even longer growth hormone suppression but there were side-effects seen in some patients. Long-term treatment with 100 μg, subcutaneously, twice daily caused growth hormone suppression in all patients studied but some escape was seen at the end of the 12-hour study period. When bromocriptine responses were compared to those of somatostatin in the same patients, somatostatin caused better growth hormone suppression in 7 out of 8 patients studied; addition of bromocriptine to somatostatin did not cause better growth hormone suppression in 4 out of the 5 patients studied than somatostatin octapeptide alone.

We conclude that somatostatin octapeptide is a significant advance in the medical treatment of acromegaly.


Growth Hormone Growth Hormone Level Growth Hormone Release Growth Hormone Suppression Octapeptide Analogue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brazeau P, Vale W, Burgus R, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 178:77–9.Google Scholar
  2. 2.
    Besser GM, Mortimer CH, McNeilly AS, et al. Longterm infusion of growth hormone release inhibiting hormone in acromegaly: effects on pituitary and pancreatic hormones. Br Med J 1974; 4:620–7.Google Scholar
  3. 3.
    Bauer W, Briner U, Doepfner W, et al. Somatostatin 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133–40.Google Scholar
  4. 4.
    Ching LJ, Sandler LM, Karenzlin ME, Burrin JM, Joplin GF, Blood SR. Longterm treatment of acromegaly with a long acting analogue of somatostatin. Br Med J 1985; 1: 284–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1987

Authors and Affiliations

  • G. M. Besser
    • 1
  • J. A. H. Wass
    • 1
  1. 1.Department of EndocrinologySt. Bartholomew’s HospitalLondonUK

Personalised recommendations